Buima (China) Participates in Construction of Shenzhen Kangtai Guangming Vaccine Base Project2024-11-12
Against the backdrop of the global COVID-19 pandemic, Kangtai Bio has not only showcased its robust scientific research and manufacturing prowess in the biopharmaceutical sector but also emerged as a pivotal contributor to global pandemic response efforts. As a strategic partner in the construction of Kangtai Bio’s vaccine production and R&D hub, Buima Company delivered approximately 40,000 square meters of premium cleanroom enclosure systems—including L50 and L100 cleanroom panel solutions—to the project. These systems, engineered for exceptional panel anti-detachment performance, fire resistance, and thermal insulation, meet the stringent cleanliness standards required for vaccine production, thereby establishing a solid foundation for the facility’s advanced R&D and manufacturing capabilities....
